Bicyclo Patents (Class 514/681)
  • Patent number: 6632843
    Abstract: This invention relates to the use of a composition for local percutaneous delivery of a drug such as a muscle relaxant, more particularly cyclobenzaprine in an organogel cream. The composition is applied by the patient directly to the skin over accessible muscles of mastication i.e., masseter and temporalis. The composition is rapidly absorbed through the skin to provide control of harmful habits such as bruxism and tooth clenching. The composition can also be applied to the skin overlying these muscles to control muscle hyperactivity (spasm) and/or trigger points, from other causes. The composition can be formulated to include another active agent such as a non-steroidal anti-inflammatory, for example ketoprofen.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: October 14, 2003
    Inventor: Mark Friedman
  • Patent number: 6576660
    Abstract: Compounds that inhibit 5-alpha-reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: June 10, 2003
    Assignee: Arch Development Corporation
    Inventors: Shutsung Liao, Richard A. Hiipakka
  • Publication number: 20030096847
    Abstract: Amide compounds of the formula: 1
    Type: Application
    Filed: November 1, 2002
    Publication date: May 22, 2003
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Akira Yamada, Satoshi Aoki
  • Patent number: 6563008
    Abstract: Novel intermediates of Formula IV wherein the substituents are as defined in the specification and a process for preparing the same.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 13, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Dominique Lesuisse, Jean-Georges Teutsch
  • Publication number: 20030073738
    Abstract: A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K3. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin K3 is in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.
    Type: Application
    Filed: June 3, 2002
    Publication date: April 17, 2003
    Inventors: Jacques Gilloteaux, Henryk S. Taper, James M. Jamison, Jack L. Summers
  • Patent number: 6548679
    Abstract: The present invention provides compounds of general formula I or II: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I or II.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: April 15, 2003
    Assignee: The Regents of the University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Patent number: 6500416
    Abstract: There are described a flowable composition for controlling harmful insects and representatives of the order Acarina, comprising at least one pesticidally active compound, one or more signal substances selected from the group consisting of pheromones, kairomones and attractants, a UV absorber or a UV absorber mixture and, if appropriate, one or more additives selected from the group consisting of viscosity-regulating thickeners, fillers, solvents and other formulation auxiliaries, which composition comprises 40 to 98% by weight of the UV absorber or the UV absorber mixture, 0.01 to 30% by weight of one or more signal substance(s) and 0.1 to 20% by weight of one or more pesticidally active compound(s) of the formulae (I) to (V) as specified, and a method of controlling harmful insects and representatives of the order Acarina using this composition.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: December 31, 2002
    Assignee: Syngenta Crop Protection, Inc.
    Inventors: Dieter Hofer, Max Angst, Pierre-Joseph Charmillot
  • Patent number: 6482846
    Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: November 19, 2002
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6465011
    Abstract: The present invention is directed to a solid formulation comprising the lipid-regulating agent dispersed in a hydrophilic, amorphous polymer in which said lipid-regulating agent is present as a meta-stable, amorphous phase.
    Type: Grant
    Filed: May 29, 1999
    Date of Patent: October 15, 2002
    Assignee: Abbott Laboratories
    Inventors: Devalina Law, Steven L. Krill, Eric A. Schmitt, James J. Fort
  • Patent number: 6462066
    Abstract: Methods and compositions for treatment of, or protection from, neuropathy resulting from reperfusion injury upon reversal of an ischemic condition, comprising treatment or prophylactic treatment of the patient with an antagonist of the type 3 ryanodine receptor, such that a rise in cytosolic Ca2+ concentration is prevented. Therapeutic compositions containing dantrolene or aminodantrolene are administered to the patient to prevent a rise in cytosolic Ca2+ that would otherwise result in Ca2+-mediated neuronal damage. Treatment of ischemic optic neuropathy by this method is shown, and the methods and compositions presented are also applicable to other ischemic reperfusion neuropathies, such as stroke, reperfusion injury after TPA treatment/carotid endarterectomy, seizures, and excitotoxic retinal damage in glaucoma.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: October 8, 2002
    Assignee: University of South Florida
    Inventors: Harpal S. Mangat, Gerry Ballough, Gary Brown
  • Patent number: 6455578
    Abstract: The present invention is directed to aromatic derivatives of formula (I), wherein: R1 is (a), wherein R3 and R4 are selected from between H and OH, provided that R3 and R4 are not simultaneously H, and R2 is H; or R1 and R2 taken together, are (b), wherein R5 is selected from between CH3 and (CH2)5OH, to the iron complexes thereof, and to their use for the preparation of pharmaceutical compositions for the normalization of iron level.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: September 24, 2002
    Assignee: Laboratoire Medidom S.A.
    Inventor: Guido Di Napoli
  • Patent number: 6436423
    Abstract: A product and method for reducing and preventing the ingestion of substrates by avians wherein the substrates are disposed within an avian house. The product is a bird repellent in combination with a substrate disposed within an avian house. As a result of the reduced ingestion of substrates such as litter, healthier avians are achieved.
    Type: Grant
    Filed: June 15, 1999
    Date of Patent: August 20, 2002
    Assignee: Arkion Life Sciences
    Inventors: Kenneth E. Ballinger, Jr., Craig W. Henry
  • Patent number: 6433022
    Abstract: There is provided a method of contraception, comprising exposing a spermicidally sufficient quantity of an agent to spermatozoa. The agent is a quinone represented by the following formula: Each group A is H or an electron releasing moiety. The agent is capable of generating reactive oxygen species including free radicals, superoxide and hydrogen peroxide in the presence of spermatozoa.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: August 13, 2002
    Assignee: Medical Research Council
    Inventor: Robert John Aitken
  • Patent number: 6433021
    Abstract: Indane compounds of general formulae (1) to (4) and their pharmaceutical use, particularly to achieve mast cell stabilising activity and/or anti-inflammatory activity are described.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: August 13, 2002
    Assignee: Venantius Limited
    Inventors: Neil Frankish, Helen Sheridan, John Walsh, Michael Jordan
  • Publication number: 20020019382
    Abstract: The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
    Type: Application
    Filed: December 4, 2000
    Publication date: February 14, 2002
    Inventors: James P. Snyder, Matthew C. Davis, Brian Adams, Mamoru Shoji, Dennis C. Liotta, Eva M. Ferstl, Ustun B. Sunay
  • Patent number: 6323181
    Abstract: The present invention provides illudin analogs of the general formula I: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: November 27, 2001
    Assignee: The Regents of the University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Patent number: 6323234
    Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; composition comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: November 27, 2001
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6288126
    Abstract: A compound having the formula wherein R5 is an [A]—CH3, —[A]—C(OH)ZZ′ or —[A]—C(O)Z″ grouping where —[A]— is an alkylene, alkenylene or alkynylene radical or a single bond, and Z, Z′ and Z″ are a hydrogen atom or an optionally substituted alkyl, alkenyl, alkynyl or aryl radical; and R1, R2, R3, R4, R6, R7 and R8 are as defined in the description; the use thereof as a drug, pharmaceutical compositions containing same, a preparation method therefor, and intermediates of said method, are disclosed.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: September 11, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Dominique Lesuisse, Jean-Georges Teutsch
  • Patent number: 6264969
    Abstract: A method is described for controlling or exterminating moles through the use of a bait composition in the form of a gel, paste, or grease. The composition includes an attractant and an active ingredient capable of killing vertebrate pests. The composition is injected into a mole tunnel through a small diameter nozzle, tube or needle to avoid digging open the tunnel or causing it to collapse.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: July 24, 2001
    Assignee: Genesis Laboratories, Inc.
    Inventor: Richard M. Poche
  • Patent number: 6187822
    Abstract: The present invention pertains to a method for healing a wound in a mammal which comprises the steps of (A) providing a therapeutic wound healing composition comprising a therapeutically effective amount of an inhibitor of mono-adenosine diphosphate-ribosyl transferase to inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor; and (B) contacting the therapeutic wound healing composition with a wound in a mammal. This invention also pertains to wound healing compositions and to methods for preparing and using the wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. This invention further pertains to therapeutic dermatological-wound healing compositions useful to minimize and treat diaper dermatitis and to methods for preparing and using the therapeutic dermatological-wound healing compositions.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: February 13, 2001
    Assignee: University of Medicine & Dentistry of NJ
    Inventor: Samuel J. Leibovich
  • Patent number: 6169111
    Abstract: Conformationally rigid aryl prostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic pharmaceutical compositions comprising said prostaglandins.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: January 2, 2001
    Assignee: Alcon Laboratories, Inc.
    Inventors: Paul W. Zinke, John E. Bishop, Thomas R. Dean, Mark R. Hellberg
  • Patent number: 6133303
    Abstract: The present invention provides compounds of Formula (I). The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: October 17, 2000
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Patent number: 6103768
    Abstract: The invention described here concerns the unique utility of fatty acids and their derivatives to eradicate existing fungal and bacterial infections in plants. Also, described herein are combination treatments whereby fatty acids are used to enhance or augment the activity of fungicides, bactericides, and biological control agents.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: August 15, 2000
    Assignee: Mycogen Corporation
    Inventors: Steven D. Savage, Steven L. Evans, Robert A. Haygood, Paul S. Zorner, Keith Jones
  • Patent number: 6080791
    Abstract: A method of preventing and treating a viral condition caused by an enveloped virus is described, comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted hydroquinone and the corresponding benzoquinone, wherein said hydroquinone comprises a 2-R.sup.1, 3-R.sup.2 -1,4-hydroquinone where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring of the hydroquinone. Particularly useful compounds include 5,8-dihydro-5,8-methano-1,4-naphthalenediol, 1,4-naphthoquinone, 3', 6'-dihydroxybenzo-norbornane, tert-butylhydroquinone, other diols, e.g. 1,5-naphthalenediol, and alkylated diols, e.g. 4-methoxy-1-naphthol.
    Type: Grant
    Filed: July 24, 1992
    Date of Patent: June 27, 2000
    Assignees: Seres Laboratories, Inc., University of California
    Inventors: Dale L. Bodian, Judith M. White, Irwin D. Kuntz, Jay F. Stearns, R. Bryan Yamasaki
  • Patent number: 6080781
    Abstract: The present invention provides new tetralone or benzopyranone derivatives and a method for producing the derivatives useful for a therapeutic agent for preventing and/or treating hormone dependent diseases. The present invention is a new tetralone or benzopyranone derivative represented by a particular general formula (I). ##STR1## wherein R.sub.1 and R.sub.2 represent hydrogen, a hydroxy group, an alkyloxy group or an aralkyloxy group, respectively, R.sub.3 -R.sub.7 represent hydrogen, a hydroxy group or a straight or branched alkyl, alkyloxy or aralkyloxy group having 1-6 carbon atoms, a halogen, an amino group or an alkylene dioxy group joined at R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, R.sub.5 and R.sub.6, or R.sub.6 and R.sub.7, respectively, and A represents a methylene or oxygen.In the production, a particular tetralone or benzopyranone compound and a particular benzaldehyde compound are reacted.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: June 27, 2000
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Makoto Yoshihama, Masamichi Nakakoshi, Junji Nakamura, Shoji Nakayama
  • Patent number: 6074634
    Abstract: The present invention provides an composition for attracting noctuid and/or other lepidopteran species. Liquid and solid formulations are provided, along with methods for their use, for controlling or eliminating noctuid and/or other lepidopteran species, and/or protecting plants susceptible to noctuid and/or other lepidopteran species damage.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: June 13, 2000
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Juan D. Lopez, Jr., Ted N. Shaver, Kenneth R. Beerwinkle, Peter D. Lingren
  • Patent number: 6075044
    Abstract: The use of certain heterocyclic derivatives for treating parasitic protozoa infections in mammals, in particular bovine trichomoniasis and giardiasis, is disclosed.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: June 13, 2000
    Assignee: The Regents of the University of California
    Inventors: Ching C. Wang, John Somoza, Jon P. Page, Ronaldus Marcellus Alphonsus Knegtel, Irwin D. Kuntz, Connie M. Oshiro, A. Geoffrey Skillman
  • Patent number: 6057347
    Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: May 2, 2000
    Assignee: NitroMed, Inc.
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6051588
    Abstract: A compound comprising a non-steroidal antiinflammatory agent to which is directly or indirectly linked an NO group, a pharmaceutical composition including the compounds and methods of treatment of pain and/or inflammation using the compounds and compositions are disclosed. Also disclosed is a composition comprising a non-steroidal antiinflammatory agent and a compound that donates, transfers or releases nitric oxide.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: April 18, 2000
    Inventors: David S. Garvey, L. Gordon Letts, H. Burt Renfroe, Sang William Tam
  • Patent number: 6043286
    Abstract: Pesticidal as a pesticide against whitefly, Lepidoptera and certain fungi is provided of compound of general formula (I) ##STR1## or a salt thereof is provided, in which n represents an integer from 0 to 4; m represents an integer 0 or 1;each R independently represents a halogen atom or a nitro, cyano, hydroxyl, alkyl, alkenyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, haloalkenoxy, amino, alkylamino, dialkylamino, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, cycloalkyl, aryl or aralkyl group;R.sup.1 and R.sup.2 each independently represent an optionally substituted alkoxy group or together represent a group .dbd.O, .dbd.S or .dbd.N--OR.sup.9, where R.sup.9 represents a hydrogen atom or an optionally substituted alkyl group;R.sup.3 represents a hydroxyl group, or a group --OL where L is a leaving group, or a group which in vivo is transformed into a group --OL.sup.1 where L.sup.1 is a leaving group;R.sup.7 and R.sup.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: March 28, 2000
    Assignee: BTG International Limited
    Inventors: Bhupinder Pall Singh Khambay, Duncan Batty
  • Patent number: 5990172
    Abstract: This invention provides peptidomimetics which bind to T4 or CD4 cell receptors and are useful in inhibiting viral infectivity by viruses which bind to T4 cell receptors. More specifically, peptidomimetics of this invention can alleviate symptoms of AIDS by inhibiting binding of HIV, the virus associated with AIDS, to receptor sites in human cells susceptible to HIV infection. These peptidomimetics, in particular, inhibit binding of HIV to cells of brain membrane and the immune system. They also display substantially longer half-lives in vivo than peptide T. The compounds of this invention which bind to T4 or CD4 receptors and thereby inhibit binding of HIV, alone or in combination with one another, can be used to alleviate AIDS symptoms and ameliorate symptoms of HIV infection, especially neuronal dementias and Kaposi's sarcoma. The compounds of this invention, alone or in combination, can further be used to prevent development of AIDS in persons who might become exposed to HIV.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: November 23, 1999
    Assignee: Innapharma, Inc.
    Inventors: Matthew R. Pincus, Andrew S. Kende, Joseph J. Hlavka, Henry B. Abajian
  • Patent number: 5968482
    Abstract: The invention relates to the use of .alpha.-hydroxyketoalkyl derivatives as light protection filters for cosmetic or pharmaceutical products, the .alpha.-hydroxyketoalkyl group being linked, if appropriate via a spacer, to a chromophoric group which has an absorption maximum in a wavelength range of between 280 and 400 nm and has a conjugated .pi.-electron system of at least 8 .pi.-electrons, and to new .alpha.-hydroxyalkyl derivatives, processes for their preparation and pharmaceutical and cosmetic formulations comprising these derivatives as light protection substances.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: October 19, 1999
    Assignee: Merck Patent Gesellschaft MIT Beschrankter Haftung
    Inventors: Roland Martin, Ingeborg Stein, Ulrich Heywang, Michael Schwarz, Thekla Kurz
  • Patent number: 5968917
    Abstract: Method of treating osteoporosis according to the present invention comprises the administration to a subject in need thereof a therapeutically effective amount of diosgenin, a therapeutically effective amount of vitamin K and a therapeutically effective amount of vitamin D.
    Type: Grant
    Filed: July 13, 1998
    Date of Patent: October 19, 1999
    Assignee: The Boots Company PLC
    Inventor: Paul Rodney Clayton
  • Patent number: 5945449
    Abstract: A sterile bicarbonate concentrate for use in the present invention relates to a sterile calcium-free bicarbonate concentrate for use in peritoneal dialysis, hemofiltration, cardiac bypass surgery and in electrolyte replacement therapy.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: August 31, 1999
    Assignee: Dialysis Solutions Inc.
    Inventors: Larry Joseph Purcell, Sheldon William Tobe
  • Patent number: 5932553
    Abstract: The present invention provides illudin analogs of the general formula (I): ##STR1## where R.sub.1 is (CH.sub.2).sub.n --X--Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C.sub.1 -C.sub.8)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.4)alkyl or cyclo(C.sub.3 -C.sub.6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R.sub.2 is absent; or R.sub.1 and R.sub.2 together comprise a 5-7 membered cyclic ring;R.sub.3 is (C.sub.1 -C.sub.4)alkyl or H; R.sub.4 is H, SCH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl, O--(C.sub.5 --C.sub.12)aryl or --S--(C.sub.5 -C.sub.12)aryl; R.sub.5 is H, OH or absent; R.sub.6 is (C.sub.1 -C.sub.4)alkyl or absent; R.sub.7 is OH or OSi((C.sub.1 -C.sub.4)alkyl).sub.3 ; orR.sub.6 and R.sub.7 together are ethylenedioxy;R.sub.8 is optionally substituted (C.sub.1 -C.sub.4)alkyl; andthe bonds represented by -- are individually present or absent.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: August 3, 1999
    Assignee: The Regents of the University of California
    Inventors: Trevor C. McMorris, Michael J. Kelner
  • Patent number: 5773005
    Abstract: Strong 5.alpha.a-reductase inhibitors are extracted and fractionated from Thuja orientalis and other similar crude drugs or they may be purified as diterpenes in isolated form. The inhibitors are used either on their own or as active ingredients of therapeutics in the treatment of diseases caused by the overactivity of 5.alpha.a-reductase or the hypersecretion of androgens, such as male pattern baldness, androgenetic alopecia, hirsutism, acne, prostatomegaly and cancer of the prostate.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: June 30, 1998
    Inventors: Hidehiko Takahashi, Susumu Hara, Rieko Matsui
  • Patent number: 5770233
    Abstract: An object of the present invention is to provide an infusion preparation set (a container filled with infusion liquids) useful for preparation of an infusion liquid containing sugars, amino acids, electrolytes, a fat emulsion and vitamins. The present invention is constituted by the use of a container having two compartments which are separated from each other by a separation means, which contains an infusion liquid comprising a fat emulsion, sugars, fat-soluble vitamins and specified water-soluble vitamins in the first compartment and an infusion liquid comprising amino acids, electrolytes and other specified water-soluble vitamins in the second compartment. An infusion preparation containing sugars, amino acids, electrolytes, a fat emulsion and vitamins can be obtained easily and aseptically upon use, by simply removing a separation means and mixing the infusion liquids included in the first and second compartments.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: June 23, 1998
    Assignee: The Green Cross Corporation
    Inventors: Takae Kido, Shigeo Ii, Shun-ichi Abe, Kazumasa Yokoyama
  • Patent number: 5763479
    Abstract: A redox, hydrogen-acceptor compound, having utility in treating inflammation, is a 1,4-dioxonaphthalene or 1,4-dilminon aphthalene having either a 2,3-double bond, in which cast there are 2 and 3-substituents, or a 2,3-single bond. Examples of such compounds are menadione epoxide and water-soluble derivatives or menadione such as menadione bisulphite.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: June 9, 1998
    Assignee: KS Biomedix Ltd.
    Inventors: Joseph Chayen, Lucille Bitensky, George T. B. Frost
  • Patent number: 5720951
    Abstract: A rodenticidal bait in the form of agglomerated granules comprising: a cereal base comprising a ground cereal; a rodenticide; and a water-soluble film-forming binder.
    Type: Grant
    Filed: January 14, 1997
    Date of Patent: February 24, 1998
    Assignee: Zeneca Limited
    Inventor: Simon Dominic Baker
  • Patent number: 5716995
    Abstract: An anti-osteopathic composition comprising as an active ingredient a compound represented by the following formula (I), (II) or (III): ##STR1## which is useful for therapeutic and prophylactic treatment of osteopathia such as osteoporosis and bone fracture.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignees: Hoechst Japan Limited, Koichi Shudo
    Inventors: Koichi Shudo, Tatsuo Sugioka, Mizuho Inazu, Hideyuki Tanaka, Tsutomu Inoue, Kazuyuki Kitamura
  • Patent number: 5661123
    Abstract: The present invention provides a method for providing nutrition to non-catabolic and moderately catabolic patients. Pursuant to the present invention, the enteral composition includes a peptide based protein source of hydrolyzed whey, a lipid source, and a carbohydrate source. Preferably, the protein source includes approximately 22% to about 27% of the total calories. The composition has a caloric density of approximately 1000 Kcal/L and a low osmolality of approximately 300 to 450 mOsm/Kg H.sub.2 O. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: August 26, 1997
    Assignee: Nestec, Ltd.
    Inventors: Lance Stalker, Diana Twyman, Shen-Youn Chang, Veronique Jaussan
  • Patent number: 5599840
    Abstract: A nutritional composition, adapted for consumption by mammals, contains (1) an orally ingestible diluent or carrier, except an oily carrier or diluent which comprises C.sub.8-18 saturated fatty acids, oleic acid and derivatives of these acids, and (2) a composition of matter which consists of (a) from about 13.0 to about 27.5% by weight of at least one compound selected from linolenic acid and its salts, esters and amides, calculated as the free acid, and (b) about 87.0 to about 72.5% by weight of at least one compound selected from linoleic acid and its salts, esters and amides thereof, calculated as the free acid, the salts, esters and amides of linolenic and linoleic acid being both physiologically hydrolyzable and pharmacologically acceptable. The invention also relates to a method for treating a mammal for the purpose of inducing therein at least one physiological effect selected from memory enhancement and analgesia, by administration of an effective amount of the nutritional composition.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: February 4, 1997
    Assignee: Bar Ilan University
    Inventor: Shlomo Yehuda
  • Patent number: 5589514
    Abstract: Compounds of formula I, ##STR1## wherein the substituents R.sub.1 -R.sub.4 and a have the given meanings and show an activity against inflammatory conditions.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: December 31, 1996
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Ramachandra G. Naik, Vilas N. Mumbaikar, Rangarajan Vasumathy, Aftab D. Lakdawala, Mandakini V. Shirole, Bansi Lal, Jurgen Blumbach, Klaus U. Weithmann, Robert R. Bartlett
  • Patent number: 5534546
    Abstract: New indene derivative, obtainable from etiolated seedlings of Adlay and shown by Formulas (1) and (2) given below, have antimicrobial effects and can serve as effective components of antimicrobial agents: ##STR1##
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: July 9, 1996
    Assignees: Kagome Kabushiki Kaisha, Youji Sonoda
    Inventors: Yukio Ishiguro, Youji Sonoda, Kenji Okamoto, Takamitsu Okamoto, Hideki Sakamoto
  • Patent number: 5510391
    Abstract: A vitamin K mixture is used in a topical application for the treatment of blood vessel disorders of the skin which include, but are not limited to, actinic and iatrogenic purpura, lentigines and other vascular problems of the skin and subcutaneous tissue. The formulation of the mixture includes a number of the following substances: vitamin K, 95% ethyl alcohol SD40, isopropyl alcohol 99%, benzyl alcohol, lecithin granules, isopropyl palmitate NF, propyl paraben, methyl paraben, Pluronic F-127 NF, Dowicil 200 and preserved water. The concentrations of the substituent compounds vary in the different formulations of the vitamin K cream.
    Type: Grant
    Filed: October 22, 1993
    Date of Patent: April 23, 1996
    Assignee: Mayapple Holdings, LLC
    Inventor: Melvin L. Elson
  • Patent number: 5478569
    Abstract: Stable, cold water-dispersible, liquid or pulverous compositions of fat-soluble substances which contain fish gelatin as the protective colloid and a method of making same are described.
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: December 26, 1995
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Berneis, Peter Schuler
  • Patent number: 5476860
    Abstract: Diaromatic compounds, characterized in that they correspond to the following general formula: ##STR1## in which: R.sub.1 is --CH.sub.3, --CH.sub.2 OH, --COR.sub.8 or --CH.sub.2 OCOR.sub.9, R.sub.8 is H, OH, --OR.sub.10, --N(rr') or alkyl, R.sub.10 is alkyl, alkenyl, aryl or aralkyl, r and r' being H, alkyl, aryl, aralkyl, etc., r and r' together form a heterocycle, R.sub.9 is alkyl, alkenyl or a sugar residue, R.sub.2 and R.sub.3 are --OR.sub.11 or --OCOR.sub.11, R.sub.11 is H, alkyl, fluoroalkyl, aryl or aralkyl, R.sub.3 in addition being H, R.sub.4 is H, OH, alkyl, alkoxy, F, Cl or --CF.sub.3, R.sub.5 and R.sub.7 are H, OH, alkoxy, .alpha.-substituted alkyl or .alpha.,.alpha.'-disubstituted alkyl, etc., R.sub.6 is H, OH, alkyl, alkoxy, cycloalkyl, etc., R.sub.5 and R.sub.7 cannot simultaneously be OH or alkoxy and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 cannot simultaneously be H, R.sub.5 and R.sub.6 or R.sub.6 and R.sub.
    Type: Grant
    Filed: December 8, 1993
    Date of Patent: December 19, 1995
    Assignee: Centre International de Recherches Dermatologiques (CIRD Galderma)
    Inventor: Jean-Michel Bernardon
  • Patent number: 5464866
    Abstract: Substituted hydrindanes and their use in controlling angiogenesis-dependent diseases in warm blooded animals are disclosed.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: November 7, 1995
    Assignee: Alcon Laboratories, Inc.
    Inventors: Abbot F. Clark, Raymond E. Conrow
  • Patent number: 5446069
    Abstract: Disclosed are compounds of formula ##STR1## wherein F represents: ##STR2## or a pharmaceutically acceptable salt. The compounds are useful in treating hyperproliferative skin disease, allergic reactions and inflamation.
    Type: Grant
    Filed: March 29, 1993
    Date of Patent: August 29, 1995
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Pietro Mangiaracina, Michael J. Green, Ashit K. Ganguly
  • Patent number: RE37087
    Abstract: There are provided new alkane and alkoxyalkane derivatives of the general formula I in which R1, R2, R3, R4 and A have the meanings given in the description, processes for their preparation and insecticidal and acaricidal compositions containing these compounds.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: March 6, 2001
    Assignee: Schering Aktiengesellschaft
    Inventors: Helga Franke, Heinrich Franke, Hans-Rudolf Kruger, Hartmut Joppien, Dietrich Baumert, David Giles